NIP
DAWN

Nicholas Investment Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Nicholas Investment Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-361,767
Closed -$5.98M – 204
2024
Q1 		$5.98M Buy
361,767
+58,449
+19% +$875K 0.61% 54
2023
Q4 		$4.43M Sell
303,318
-1,885,336
-86% -$22.9M 0.52% 72
2023
Q3 		$26.9M Sell
2,188,654
-48,457
-2% -$632K 2.01% 13
2023
Q2 		$26.7M Buy
2,237,111
+633,721
+40% +$8.28M 1.83% 16
2023
Q1 		$21.4M Buy
1,603,390
+816,836
+104% +$16M 1.63% 20
2022
Q4 		$16.9M Buy
786,554
+29,147
+4% +$598K 1.48% 16
2022
Q3 		$15.2M Buy
+757,407
New +$16.1M 1.41% 18

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nicholas Investment Partners's DAWN Position: Q2 2024 in Review

Nicholas Investment Partners sold out of Day One Biopharmaceuticals (DAWN) in Q2 2024, closing a stake of 361,767 shares — an estimated $5.98M sold.

Nicholas Investment Partners first reported a position in DAWN in Q3 2022 and held it in 7 quarters. The position peaked at $26.9M in Q3 2023. 156 funds tracked by Wall St. Rank hold DAWN as of Q2 2024.

  • Nicholas Investment Partners reported no remaining Day One Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 361,767 Day One Biopharmaceuticals shares in Q2 2024, an estimated $5.98M.
  • Nicholas Investment Partners first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 7 quarters.
  • Nicholas Investment Partners's Day One Biopharmaceuticals position peaked at $26.9M in Q3 2023.
  • 156 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2024.

Based on Nicholas Investment Partners's 13F filing for Q2 2024, filed 8 Aug 2024.